To include your compound in the COVID-19 Resource Center, submit it here.

Vadastuximab talirine: Additional Phase I data

Data from 49 evaluable newly diagnosed patients with CD33-positive AML in an open-label, U.S. Phase I trial showed that IV

Read the full 209 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE